FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Cancer Drug Reactivates Multiple Myeloma CAR‑T Therapy
Original story from the Technical University of Munich Researchers have uncovered a protein mechanism that weakens multiple myeloma…
Why are men more likely to develop multiple myeloma than women?
A study has unearthed potential reasons for sex differences that are observed in the clinical presentation of patients…
Largest Immune Cell Atlas of Multiple Myeloma Predicts Recurrence Risk
Credit: Md Saiful Islam Khan / iStock / Getty Images Plus Scientists across six leading U.S. institutions have…
Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T…